177 related articles for article (PubMed ID: 36419394)
41. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
[TBL] [Abstract][Full Text] [Related]
42. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Parent P; Auclin E; Patrikidou A; Mezquita L; Martínez Chanzá N; Dumont C; Rodriguez-Vida A; Llacer C; Lozano R; Ratta R; Merseburger AS; Sternberg CN; Baciarello G; Colomba E; Fuerea A; Besse B; Loriot Y; Lavaud P
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831409
[TBL] [Abstract][Full Text] [Related]
44. Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Nakamura K; Ishiyama Y; Nemoto Y; Ishihara H; Tachibana H; Fukuda H; Shinmura H; Hashimoto Y; Yoshida K; Iizuka J; Ishida H; Kondo T; Takagi T
Int J Clin Oncol; 2023 Jul; 28(7):913-921. PubMed ID: 37103730
[TBL] [Abstract][Full Text] [Related]
45. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
46. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
Meyers DE; Stukalin I; Vallerand IA; Lewinson RT; Suo A; Dean M; North S; Pabani A; Cheng T; Heng DYC; Bebb DG; Morris DG
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684111
[TBL] [Abstract][Full Text] [Related]
47. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.
Zhang Q; Gong X; Sun L; Miao L; Zhou Y
Front Oncol; 2022; 12():791496. PubMed ID: 35924149
[TBL] [Abstract][Full Text] [Related]
48. The Lung Immune Prognostic Index May Predict the Efficacy of Different Treatments in Patients with Advanced NSCLC: A Meta-Analysis.
Xie J; Zang Y; Liu M; Peng L; Zhang H
Oncol Res Treat; 2021; 44(4):164-175. PubMed ID: 33657566
[TBL] [Abstract][Full Text] [Related]
49. Sixth-Week Immune-Nutritional-Inflammatory Biomarkers: Can They Predict Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
Olgun P; Diker O
Curr Oncol; 2023 Dec; 30(12):10539-10549. PubMed ID: 38132403
[TBL] [Abstract][Full Text] [Related]
50. Association between the modified lung immune predictive index and clinical outcomes of advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors combined with chemotherapy.
Xu H; Tian W; Lin X; Leong TL; Seki N; Ichiki Y; Su S; Chen J; Li Y; Ye J
J Thorac Dis; 2023 Nov; 15(11):6279-6290. PubMed ID: 38090322
[TBL] [Abstract][Full Text] [Related]
51. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
52. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.
Zhou Q; Deng G; Wang Z; Dai G
Front Surg; 2022; 9():1002075. PubMed ID: 36684178
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Value of the Lung Immune Prognostic Index for Metastatic Non-Small Cell Lung Cancer Patients: A Chinese Cohort Study.
Huang J; Pu H; He J; Tang X
Int J Gen Med; 2023; 16():881-893. PubMed ID: 36915421
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Significance of the Lung Immune Prognostic Index in Patients with Resected Esophageal Squamous Cell Carcinoma.
Feng JF; Zhao JM; Chen S; Chen QX
Cancer Manag Res; 2021; 13():2811-2819. PubMed ID: 33814930
[TBL] [Abstract][Full Text] [Related]
56. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
[TBL] [Abstract][Full Text] [Related]
57. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
58. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
59. C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.
Sonehara K; Ozawa R; Hama M; Nozawa S; Agatsuma T; Nishie K; Kato A; Matsuo A; Araki T; Komatsu M; Tateishi K; Hanaoka M
Thorac Cancer; 2023 Feb; 14(6):636-642. PubMed ID: 36635979
[TBL] [Abstract][Full Text] [Related]
60. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]